Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Brii Biosciences
The two companies have partnered on VBI-2601 since 2018, and Brii is now taking global rights to that program as well as licensing rights to VBI’s hepatitis B vaccine.
COVID-19 has highlighted the need for potent, safe and effective antiviral therapies for infectious diseases and now one well-known Chinese researcher is tackling hepatitis B and D though a homegrown drug discovery approach. He talks to Scrip in this wide-ranging audio interview.
Two bioventures in China have jettisoned immuno-oncology assets, including PD-1/L1- and CD47-targeting agents, while four other firms have disclosed shifts in R&D priorities and employee lay-offs as they deal with challenging conditions.
From being little known to sought after by millions, Pfizer’s oral antiviral Paxlovid is fast becoming the most pursued medicine in China, amid the largest outbreak of COVID-19 infections the world has yet seen.
- Large Molecule
- Other Names / Subsidiaries
- Brii Biosciences Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.